J&J Agrees to Pay at Least $5.5 Billion to Resolve 76,000 Talc-Cancer Claims
After trial: Settlement minimum; the total is at least $5.5 billion.
Won by Ashcraft & Gerel, LLP.
After fifteen years of litigation and three failed bankruptcy maneuvers by Johnson and Johnson subsidiaries, Ashcraft and Gerel attorneys R. Bryant McCulley and Michelle Parfitt helped negotiate a global, uncapped settlement of at least $5.5 billion covering approximately 76,000 ovarian-cancer claims.
What happened
For decades, Johnson and Johnson marketed its talc-based baby powder as a safe, gentle product. Beginning in the 2010s, plaintiffs across the country alleged that long-term exposure to talc contaminated with asbestos caused ovarian cancer, and thousands of women filed suit. By the time cases consolidated in the District of New Jersey as MDL No. 2738, more than 76,000 claimants had joined the litigation.
The road to resolution was not straight. J&J twice created a subsidiary, LTL Management, and pushed it into bankruptcy, attempting to channel the talc liability into a restructuring process that would limit payouts and block jury trials. Federal courts rejected both efforts. A third bankruptcy attempt also failed. Meanwhile, individual cases produced a wide range of jury results, and a federal judge overseeing the MDL raised questions about the sufficiency of general causation evidence, strengthening J&J's hand at the negotiating table.
Through all of that, plaintiffs' counsel kept pressing. R. Bryant McCulley of Ashcraft and Gerel served on the three-member Plaintiffs' Negotiation Committee alongside Christopher Seeger of Seeger Weiss and Hunter Shkolnik of Napoli Shkolnik, the core team that met directly with J&J's litigation leadership. Michelle Parfitt, also of Ashcraft and Gerel, served as Co-Lead Counsel on the Plaintiffs' Executive Committee, which oversaw the broader litigation strategy.
On July 27, 2026, the parties announced a global settlement. J&J agreed to pay a minimum of $5.5 billion, with the total uncapped, meaning qualifying claimants would be paid in full regardless of how many ultimately enrolled. The deal covers federal cases in MDL 2738 and related state court proceedings. An initial payment of $3 billion was scheduled for 2027, with remaining amounts to follow in 2028, completing the payout within eighteen months. The settlement requires acceptance by at least 95 percent of eligible claimants to take effect.
J&J, which pulled its talc-based baby powder from US shelves in 2020 and discontinued worldwide sales in 2023, denied that its products caused cancer. The company's litigation head called the deal a way to 'put this matter behind it.' Plaintiffs' counsel described it as providing fair compensation after a decade and a half of hard-fought cases. Law.com (The American Lawyer) reported the settlement on July 27, 2026, citing McCulley by name as one of the three lead negotiators.
Sources
This account is drawn from contemporaneous public reporting and the court record.
- 1.Law.com (The American Lawyer): J&J Settles 76,000 Talcum Powder Lawsuits for at Least $5.5B (July 27, 2026)·Archived copy
- 2.Insurance Journal: Johnson and Johnson Announces $5.5 Billion Settlement of Talc Lawsuits (July 28, 2026)·Archived copy
- 3.Fox Business: Johnson and Johnson Agrees to Pay $5.5B to Settle Talc Lawsuits·Archived copy
- 4.Seeger Weiss LLP: Plaintiffs Reach Uncapped Global Settlement With J&J·Archived copy
More proven verdicts from Ashcraft & Gerel, LLP
All Ashcraft & Gerel, LLP proven verdicts →As chair of the plaintiffs' negotiating committee and Liaison Counsel in the Vioxx multidistrict litigation, Russ Herman directed the negotiations that produced a $4.85 billion settlement with Merck resolving approximately 45,000 to 50,000 personal-injury claims.
An L.A. jury awarded Eva Echeverria $417 million after finding that decades of Johnson & Johnson Baby Powder use caused her ovarian cancer, though the trial judge later vacated the verdict and the Court of Appeal affirmed the vacatur.
A federal jury in Cleveland awarded $5 million to Paul Decker and his wife after finding that GE Healthcare failed to adequately warn patients about the risk of nephrogenic systemic fibrosis from its Omniscan MRI contrast agent, making Decker the first gadolinium NSF case in the country to reach a jury verdict.
A seven-year-old boy lost three fingers on his left hand when an old Navy practice bomb from the Duck, North Carolina bombing range exploded in February 1967. After a bench trial under the Federal Tort Claims Act, the court found the Navy negligent for leaving live bombs accessible on an unfenced range and awarded the boy $160,000, plus $1,700.30 to his father for medical expenses.
Related product liability verdicts
Sullivan Papain was among the firms representing New York State against Philip Morris, R.J. Reynolds, Brown & Williamson, and Lorillard, securing a $25 billion recovery through the 1998 Master Settlement Agreement.
C. Steven Yerrid, the youngest of Florida's 11-lawyer 'Dream Team,' added racketeering and conspiracy charges that tripled the damages ceiling, helping the state secure what was then the largest civil settlement in American history against the tobacco industry.
As co-lead counsel in the federal Roundup multidistrict litigation and the first firm to sue Monsanto in 2015, Weitz and Luxenberg helped negotiate a $10.9 billion settlement resolving approximately 125,000 non-Hodgkin lymphoma claims against Bayer-owned Monsanto.
As chair of the plaintiffs' negotiating committee and Liaison Counsel in the Vioxx multidistrict litigation, Russ Herman directed the negotiations that produced a $4.85 billion settlement with Merck resolving approximately 45,000 to 50,000 personal-injury claims.